3D Medicines (HKSE:01244) Operating Cash Flow per Share : HK$-0.71 (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Operating Cash Flow per Share?

3D Medicines's operating cash flow per share for the six months ended in Dec. 2023 was HK$0.11. 3D Medicines's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.71.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 18.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for 3D Medicines's Operating Cash Flow per Share or its related term are showing as below:

HKSE:01244' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 18.8 Med: 18.8 Max: 18.8
Current: 18.8

During the past 4 years, 3D Medicines's highest 3-Year average Operating Cash Flow per Share Growth Rate was 18.80% per year. The lowest was 18.80% per year. And the median was 18.80% per year.

HKSE:01244's 3-Year OCF Growth Rate is ranked better than
67.18% of 1237 companies
in the Biotechnology industry
Industry Median: 3.3 vs HKSE:01244: 18.80

3D Medicines Operating Cash Flow per Share Historical Data

The historical data trend for 3D Medicines's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Operating Cash Flow per Share Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-1.29

-1.81

-6.84

-0.69

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial			-	-0.39	-0.84	-0.82	0.11

Competitive Comparison of 3D Medicines's Operating Cash Flow per Share

For the Biotechnology subindustry, 3D Medicines's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3D Medicines's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Price-to-Operating-Cash-Flow falls into.

3D Medicines Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

3D Medicines's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-157.956	/	228.469
	=	-0.69

3D Medicines's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	25.925	/	232.352
	=	0.11

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.71

3D Medicines Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines